36843841|t|Tivantinib alleviates inflammatory diseases by directly targeting NLRP3.
36843841|a|NLRP3 inflammasome-mediated immune responses are involved in the pathogenesis of multiple inflammatory diseases, but few clinical drugs are identified that directly target the NLRP3 inflammasome to treat these diseases to date. Here, we show that the anticancer agent tivantinib is a selective inhibitor of NLRP3 and has a strong therapeutic effect on inflammasome-driven disease. Tivantinib specifically inhibits canonical and non-canonical NLRP3 inflammasome activation without affecting AIM2 and NLRC4 inflammasome activation. Mechanistically, Tivantinib inhibits NLRP3 inflammasome by directly blocking NLRP3 ATPase activity and subsequent inflammasome complex assembly. In vivo, Tivantinib reduces IL-1beta production in mouse models of lipopolysaccharide (LPS)-induced systemic inflammation, monosodium urate (MSU)-induced peritonitis and Con A-induced acute liver injury (ALI), and also has remarkable preventive and therapeutic effects on experimental autoimmune encephalomyelitis (EAE). In conclusion, our study identifies the anticancer drug tivantinib as a specific inhibitor of NLRP3 and provides a promising therapeutic agent for inflammasome-driven disease.
36843841	0	10	Tivantinib	Chemical	MESH:C551661
36843841	22	43	inflammatory diseases	Disease	MESH:D007249
36843841	66	71	NLRP3	Gene	216799
36843841	73	78	NLRP3	Gene	216799
36843841	163	184	inflammatory diseases	Disease	MESH:D007249
36843841	249	254	NLRP3	Gene	216799
36843841	341	351	tivantinib	Chemical	MESH:C551661
36843841	380	385	NLRP3	Gene	216799
36843841	454	464	Tivantinib	Chemical	MESH:C551661
36843841	515	520	NLRP3	Gene	216799
36843841	563	567	AIM2	Gene	383619
36843841	572	577	NLRC4	Gene	268973
36843841	620	630	Tivantinib	Chemical	MESH:C551661
36843841	640	645	NLRP3	Gene	216799
36843841	757	767	Tivantinib	Chemical	MESH:C551661
36843841	776	784	IL-1beta	Gene	16176
36843841	799	804	mouse	Species	10090
36843841	815	833	lipopolysaccharide	Chemical	MESH:D008070
36843841	835	838	LPS	Chemical	MESH:D008070
36843841	848	869	systemic inflammation	Disease	MESH:D007249
36843841	871	887	monosodium urate	Chemical	MESH:D014527
36843841	889	892	MSU	Chemical	MESH:D014527
36843841	902	913	peritonitis	Disease	MESH:D010538
36843841	932	950	acute liver injury	Disease	MESH:D017114
36843841	952	955	ALI	Disease	MESH:D017114
36843841	1020	1061	experimental autoimmune encephalomyelitis	Disease	MESH:D004681
36843841	1063	1066	EAE	Disease	MESH:D004681
36843841	1125	1135	tivantinib	Chemical	MESH:C551661
36843841	1163	1168	NLRP3	Gene	216799
36843841	Negative_Correlation	MESH:C551661	16176
36843841	Negative_Correlation	MESH:C551661	MESH:D010538
36843841	Positive_Correlation	MESH:D014527	MESH:D010538
36843841	Negative_Correlation	MESH:C551661	MESH:D004681
36843841	Negative_Correlation	MESH:C551661	216799
36843841	Positive_Correlation	MESH:D008070	MESH:D007249
36843841	Association	MESH:D007249	216799
36843841	Negative_Correlation	MESH:C551661	MESH:D007249
36843841	Negative_Correlation	MESH:C551661	MESH:D017114

